Screening
Winter, M., et al. (2018). Establishing MALDI-TOF as versatile drug discovery readout to dissect the PTP1B enzymatic reaction. SLAS DISCOVERY: Advancing Life Sciences R&D
Screening
Lo, C., et al. (2018). A novel small molecule screening platform for disrupting toxic tau oligomers in cells. bioRxiv
Cell-based assays
Wang, J., et al. (2019). Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature medicine
Cell-based assays
Klanert, G., et al. (2019).. A cross-species whole genome siRNA screen in suspension-cultured Chinese hamster ovary cells identifies novel engineering targets. Scientific Reports
Cell-based assays
Lesch, M., et al. (2019). RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals. PLoS pathogens
Cell-based assays
Harris, I., et al. (2019).Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell metabolism
Cell-based assays
Tooze, S., et al. (2019).MDH1 and MPP7 regulate autophagy in pancreatic ductal adenocarcinoma. Cancer research
Cell-based assays
Mane, S., et al. (2019). Ascorbyl stearate stimulates cell death by oxidative stress-mediated apoptosis and autophagy in HeLa cervical cancer cell line in vitro. 3 Biotech
Cell-based assays
Van Der Steen, N., et al. (2019). Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. Biochemical pharmacology
Cell-based assays
Lv, J., et al. (2018). Activation of A1 and A2a adenosine receptors promotes neural progenitor cell proliferation. Brain research
Cell-based assays
Miess, H., et al. (2018). The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene
Cell-based assays
Lavarone, C., et al. (2019). Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness. Molecular Cancer Therapeutics